Beam Therapeutics Inc. Common Stock (BEAM)
Beam Therapeutics Inc. (BEAM) is a biotechnology company focused on developing precision genetic medicines using base editing technology. Founded to create targeted therapies for genetic diseases, Beam Therapeutics leverages its innovative editing platform to make precise, single-nucleotide modifications in DNA, aiming to treat serious medical conditions with fewer off-target effects.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| March 3, 2014 | $0.23 | 2014-02-04 | 2014-02-06 |
| December 2, 2013 | $0.23 | 2013-11-04 | 2013-11-06 |
| September 3, 2013 | $0.23 | 2013-08-12 | 2013-08-14 |
| June 3, 2013 | $0.23 | 2013-05-06 | 2013-05-08 |
| March 1, 2013 | $0.23 | 2013-02-04 | 2013-02-06 |
Dividends Summary
- Beam Therapeutics Inc. Common Stock has issued 41 dividend payments over the past 10 years
- The most recent dividend was paid 4219 days ago, on March 3, 2014
- The highest dividend payed out to investors during this period was $0.44 per share
- The average dividend paid during this period was $0.29 per share.
Company News
Several healthcare and AI-driven companies are demonstrating significant potential in transforming medical technologies, offering innovative therapies and solutions across various medical domains like gene editing, telehealth, and precision medicine.
Beam Therapeutics announced that the FDA has granted orphan drug designation to BEAM-302, a potential treatment for alpha-1 antitrypsin deficiency (AATD), a rare genetic disorder affecting the lungs and liver. The designation provides benefits to support the development and evaluation of BEAM-302, which has shown promising initial safety and efficacy data in a Phase 1/2 trial.
Cathie Wood's Ark Invest reduced its stake in Tesla by $8 million, despite a recent bullish outlook on the company's potential in the autonomous taxi sector.
Beam Therapeutics is advancing its gene editing therapies, with its leading candidate BEAM-101 in phase I/II trials for sickle cell disease. The company's pipeline is progressing well, and it has established promising collaborations with Eli Lilly and Pfizer, providing financial support and potential acceleration of its programs.
